Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

证券日报网讯 11月21日晚间，我武生物发布公告称，日前，浙江我武生物科技股份有限公司（以下简 称"公司"）从国家药品监督管理局政务服务门户网站下载获得《药物临床试验补充申请批准通知书》， 由公司提交的"豚草花粉点刺液"药物临床试验补充申请获得批准。 （文章来源：证券日报） ...

格隆汇11月21日丨我武生物(300357.SZ)公布，公司从国家药品监督管理局政务服务门户网站下载获得 《药物临床试验补充申请批准通知书》，由公司提交的"豚草花粉点刺液"药物临床试验补充申请获得批 准。适应症：用于皮肤点刺试验，辅助诊断与豚草花粉致敏相关的I型变态反应性疾病。 ...

每经AI快讯，11月21日，我武生物(300357.SZ)公告称，公司提交的"豚草花粉点刺液"药物临床试验补充 申请获得批准。该药品注册申请人为我武生物，注册分类为治疗用生物制品，剂型为皮肤点刺试剂，适 应症为用于皮肤点刺试验，辅助诊断与豚草花粉致敏相关的I型变态反应性疾病。此次批准内容为增加 总变应原活性为3500DU/ml，每瓶装量为2毫升规格制剂。公司将根据进展情况及时履行信息披露义 务。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

我武生物公告，日前，公司从国家药品监督管理局政务服务门户网站下载获得《药物临床试验补充申请 批准通知书》（通知书编号：2025LB00830），由公司提交的"豚草花粉点刺液"药物临床试验补充申请 获得批准。批准内容如下：同意增加总变应原活性为3500DU/ml，每瓶装量为2毫升规格制剂。 ...